1-8 of 8
K Taylor
Close
Sort by
Journal Articles

Development of Anti-IL-1R3 Monoclonal Antibodies for Treating Cancer and IL-1 Family-Mediated Inflammation

Jesper F Højen, MD, Megan K Taylor, Tania Azam, Stephan Fischer, Daniel A Pollyea, MD, Craig T Jordan, PhD, Charles A. Dinarello, MD
Journal: Blood
Blood (2016) 128 (22): 5224.
https://doi.org/10.1182/blood.V128.22.5224.5224
Published: 2016
Journal Articles

Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells

Keli L. Hippen, Paul Harker-Murray, Stephen B. Porter, Sarah C. Merkel, Aryel Londer, Dawn K. Taylor, Megan Bina, Angela Panoskaltsis-Mortari, Pablo Rubinstein, Nico Van Rooijen, Tatiana N. Golovina, Megan M. Suhoski, Jeffrey S. Miller, John E. Wagner, Carl H. June, James L. Riley, Bruce R. Blazar
Journal: Blood
Blood (2008) 112 (7): 2847–2857.
https://doi.org/10.1182/blood-2008-01-132951
Published: 2008
Includes: Supplemental data
Journal Articles

The Frequency of Detection of BCR-ABL Mutations in Imatinib Treated Patients with Chronic Phase CML Who Attain a Complete Cytogenetic Response (CCR) Does Not Diminish with Increasing Duration of CCR but the Associated Loss of Response Is Usually Gradual.

Susan Branford, Z. Rudzki, A. Grigg, J. Seymour, P. Browett, K. Taylor, R. Herrmann, A. Schwarer, C. Arthur, K. Lynch, T. Hughes
Journal: Blood
Blood (2004) 104 (11): 271.
https://doi.org/10.1182/blood.V104.11.271.271
Published: 2004
Journal Articles

BCR-ABL Levels Continue To Decrease up to 42 Months after Commencement of Standard Dose Imatinib in Patients with Newly Diagnosed Chronic Phase CML Who Achieve a Major Molecular Response.

Susan Branford, Z. Rudzki, A. Grigg, J. F. Seymour, K. Taylor, P. Browett, A. Schwarer, K. Bradstock, C. Arthur, S. Durrant, D. Ma, D. Joske, K. Lynch, T. Hughes
Journal: Blood
Blood (2004) 104 (11): 274.
https://doi.org/10.1182/blood.V104.11.274.274
Published: 2004
Journal Articles

Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.

Timothy Hughes, S. Branford, J. Reynolds, J. Seymour, K. Taylor, N. Guzzo-Pernell, R. Filshie, C. Arthur, A. Schwarer, M. Hertzberg, Z. Rudzki, M. Copeman, K. Lynch, A. Grigg
Journal: Blood
Blood (2004) 104 (11): 1001.
https://doi.org/10.1182/blood.V104.11.1001.1001
Published: 2004
Journal Articles

Correction/Maintenance Dosing (Front Loading) of Darbepoetin alfa: Final Results from a Randomized Phase 3 Active Controlled Trial.

D. Kotasek, J.-L. Canon, J. San Miguel, M. Hedenus, L. Hendricks, G. Rossi, K. Taylor
Journal: Blood
Blood (2004) 104 (11): 1636.
https://doi.org/10.1182/blood.V104.11.1636.1636
Published: 2004
Journal Articles

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x L is an essential survival protein of human myeloma cells

Sophie Derenne, Brett Monia, Nicholas M. Dean, Jennifer K. Taylor, Marie-Josée Rapp, Jean-Luc Harousseau, Régis Bataille, Martine Amiot
Journal: Blood
Blood (2002) 100 (1): 194–199.
https://doi.org/10.1182/blood.V100.1.194
Published: 2002
Journal Articles

Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis

S Elliott, K Taylor, S White, R Rodwell, P Marlton, D Meagher, J Wiley, D Taylor, S Wright, P Timms
Journal: Blood
Blood (1992) 79 (8): 1916–1919.
https://doi.org/10.1182/blood.V79.8.1916.1916
Published: 1992